Etrolizumab vs placebo
Failure to respond at endpoint (6‐12 weeks) · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in failure to respond at week 10 compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.96 [0.75, 1.23]1 study · 119 participantsModerate